May 31 |
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
|
May 31 |
Regeneron/ Sanofi say FDA has delayed Dupixent COPD label
|
May 31 |
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
|
May 31 |
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
|
May 30 |
Biohaven doses first subject in Phase I/II tumour treatment study
|
May 29 |
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
|
May 27 |
The Biggest Biotechnology Company in Europe
|
May 26 |
The Biggest Publicly Traded Biotech Company
|
May 25 |
2 Biotech Stocks to Buy in May
|
May 24 |
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
|